I am personally very excited for the upcoming conference. Although I am not expecting any major new updates, nevertheless, updating the investment community is an important step. In addition to progressing the clinical trials, updating the investment community may be an important catalyst giving momentum to the share price. I applaud the company for taking every effort on our behalf. Biotech often moves slowly, but patience is usually rewarded. I remain long and strong!

Very relieved to hear today's news that prurisol remains on schedule and obviously no major safety concerns with increased doses.

2 phase 2 trials to be completed by end of 2017. Hopefully, with additional kevetrin Ovarian cancer trial site, that will also be completed by end of 2017.

Progress is being made, patience will be rewarded.

Good point! Management has taken huge risks in the past getting the company set up and deserve to be rewarded for their past and continued commitment.

I think today we should focus on the nice development that kevetrin has a new clinical site for trial enrollment at a very well respected and prestigious institution.

With a second site in place, small trial sample size, relatively short trial duration; this will hopefully expedite and provide proof of concept over next several months. Progress continues and therefore I remain increasingly hopeful for a bright future.

Thanks to those who have uncovered this recent development. That is the benefit of this message board and the main reason I am a participant.

Although you make some valid points, and in particular, I think we both would agree that the share price doesn't seem to reflect the clinical progress. Regardless of the reasons for that, eventually with continued successful clinical trial results, we also would both agree that the share price will undoubtedly increase. People want to make money where money is to be made. It appears to me that the market is placing a lot of risk in the company which is depressing the share price. With my due diligence and analysis following this company for the last 5+ years, I think there is a major disconnect between the current share price and actual value. This has led me to consistently increase my position.

For the benefit of the message board, I again respectfully ask you to provide your background, financial, clinical, and/or research expertise so we can add weight to your consistently negative and often derogatory viewpoints which is usually based on seemingly very little actual information.

No one is forcing anyone to buy or maintain a current position in this company. If you think it's a bad investment or the risk is not something you can afford, that is understandable and I respect that.

However, if your goal is to short the company, although it may be legal, I personally find it deceiving and unethical to others on the board.

I don't agree with your point.

Can you please enlighten the board with your background as well as medical and/or financial expertise.

I personally have both a clinical (active physician in a large trauma hospital in the northeast) as well as research background (PhD in neuroimmunology, previous dermatology, as well as bio-organic synthesis research).

Moreover, I have been involved and following the biotech and pharmaceutical sector for 25+ years.

Yes!! It is an excellent institution with a well established medical school and research center. I am really excited about this news. Certainly will add credibility and quality trial results.

That is very encouraging news, shows they have the money to increase clinical sites and pursue trial for K-OC. 10 patients undergoing 6 weeks of follow up. Hopefully, trial can be completed by end of 2017. Additionally, toxicology and PK/PD data for oral conversion and oral formulation development should allow for quicker and cheaper oral phase 2 study in 2018. This development may very likely attract some BP partnership.

3 different drugs for multiple indications/platforms. Risk/Reward is extremely favorable, especially at current prices. I added recently to an already large holding. I remain long and strong.

Timing is everything... Hindsight is 20/20... All in all, Better too early than too late!

Was interesting to see that there is not a lot of shares available at the ask price. I had to raise my order price to complete the transaction. Seems to be people are waiting to see trial results or news of BP partnership/financing. Either way, I am happy to have had the opportunity to be able to pick up some more cheap shares in the interim.

3 drugs in multiple clinical trials. Just need ONE to be successful for a very nice return on investment. I have just added more shares today to an already very significant investment. Looking forward to December 2017.

I personally don't mind waiting a few short months until December to see full top line results for prurisol trial. Rushing to see interim results may not give as a dramatic effect of efficacy (study was designed with the number of patients chosen to see statistics significance with full enrollment). Interim results are often useful to show safety, however with prurisol, based on the extensive history of abacavir use and it's close similarities, safety is not a major concern. If final trial results were a year away, I would be more curious to see interim results. Again, to me personally, I don't mind the small wait.

Certainly a benefit to having 3 drugs in active clinical trials, is that everyone can pick their own favorite. For me, it's comforting to know that we only need one success to see a significant return on investment. If we get 3 successful drugs, that will be.... (fill in with your own favorite adjectives).

I appreciated today's update. B-OM and prurisol on track to be completed by years end. Management is doing their job - keeping trials moving and updating the financial communities. Looking for the best deal whether it's BP or financial community. Patience will be rewarded!

That is correct. Once FDA approval occurs for Brilacidin - OM indication, it can be used off label for other indications. Surgeons can even apply it themselves around prosthetics to both decrease inflammation of tissue, improve wound healing and pain control, and also take advantage of its antibiotic properties.

Agree! B-OM may perhaps be the first drug to cross the finish line and receive FDA approval. With fast track status already granted and if we can get breakthrough designation with rolling review. This will be very meaningful to BP and solidify our chances of a great BP partnership.

That is amazing news, was not expecting enrollment to have been completed already, congratulations to IPIX on an amazing accomplishment!

I assume a K partnership is definitely being planned. That is the purpose of doing their small K-OC trial to obtain tumor samples to prove the mechanism of P53. Concurrently, they are working on an oral formulation. Together, an oral formulation that targets P53 with minimal side effects and toxicity will be a major breakthrough in the oncology field that has not been achieved in 20+ years. An initial partnership on Kevetrin alone will likely translate to 10x returns on current investment.

Totally concur!

So true, financials have a significantly lower role as in the past. Current phase 2's that are in progress have the funding to finish by years end. If decent trial results, partnership by years end likely, share price should be many multiples of current share price. We just need one successful trial result, additional successes are of course welcome. Risk/reward ratio for significant life changing returns are truly the most favorable of any biotech company that I am aware.

Lol, no worries, we will still extend an invitation to the club!

Not necessarily, some people were fortunate to be in this from near inception when shares were literally pennies.

However, beginning in a few months time, the current share price may also be viewed as pennies relatively speaking.

If someone can accumulate 250k, I can easily see this being $4 by year end. That would take someone into the millionaire club.

Is 250k the magic number to be in the top 1%?

The enthusiasm regarding all the potential deals and opportunities is becoming infectious. However, let's all be mindful that deals (lawyers and contracts) take time to flesh out. I assume Leo is trying to get us the best deal and he will likely want prurisol interim results data which should be forthcoming. I expect a deal to be announced closer to the 4th quarter 2017.

In the meantime, I increased my already very substantial IPIX position by 10% last week. In my opinion, stock keeps de-risking with latest trial results and share price has not caught up - this is one of the best risk/reward opportunities that I am aware of in biotech sector.

I am more than happy to wait an extra few months if it gives shareholders a much better deal. Patience will likely be rewarded.

From the American Cancer Society website:

Compassionate Drug Use

What is compassionate drug use?

Medical professionals use the term “compassionate use” to refer to the treatment of a seriously ill patient using a new, unapproved drug when no other treatments are available.

Drugs that are being tested but have not yet been approved by the US Food and Drug Administration (FDA) are called investigational drugs. These drugs are generally available only to people who are taking part in a clinical trial (a research study that is testing the drug).

Being able to use one of these drugs when you are not in a clinical trial is most commonly referred to as compassionate use.

Single patient access

Patients who don’t qualify for either clinical trials or an expanded access program (if one exists) may be able to get the unapproved new drug by applying for single patient access.

In this case, the patient’s doctor must first ask the drug company if the drug can be used for the patient and see if the drug company will supply it. If the company agrees, the doctor works with the drug company to ask the FDA to approve the drug for use by this one patient.

B-OM would be used to treat oral mucositis, a side effect of chemo and/or radiation therapy in treating cancer.

Kevetrin is our cancer killer drug. There is preliminary evidence that it may offer hope and treatment for many different types of cancer.

Well said!! Regardless of anyone's political beliefs, Senator McCain is a hero and has devoted his life to the well being of our country. Hopefully, he has a speedy recovery!

McCain has a big brain in his "head" that has a very aggressive brain tumor - he may need a high cumulative dose of radiation therapy that may cause oral mucositis. He may benefit from Brilacidin to both treat but more importantly help prevent oral mucositis from developing.

He did have the surgery, supposedly went well. Follow up care may include chemo and/or radiation therapy to prevent recurrence. Brilacidin-OM in addition to potentially treating oral mucositis, may actually prevent it!!

Just read on CNN that Senator McCain underwent brain surgery for an aggressive brain tumor and may likely undergo chemo and/or radiation therapy. Sounds like a potential candidate for Brilacidin-OM.

As always, great informative write up on seeking alpha, good to increase awareness for the benefits of potential patients/trial participants and the investment community.

Strongly agree. Trials are progressing. Likely deal within 3-6 months. Stellar investment. I continue to keep adding. Actually added 10% just today to an already very substantial position. Long and strong!

Just because they presented data on the original unblinded 19 patients for B-OM, does not mean more patients have not been added. Due to the blinding process, data can not be analyzed on a rolling basis.

Regardless, the highly encouraging previously released B-OM data, in addition to the newly released B-UP date, make a very compelling story regarding its anti-inflammatory as well as previously known antibiotic properties.

I expect after today's news, IPIX will be meeting with many of the large pharma companies over the next 1 to 6 months, and will evaluate the best deal to increase shareholder value.

This is an exciting time and the best is yet to come!

My sincere and best advice to those who are serious investors looking for serious returns, hold tight and wait for around September - December 2017 time! That is a more realistic time frame for all the phase 2 trials to conclude and to get the most realistic and best valued deal from large pharma. I am holding tight!!

Congratulations to the day traders who have made some gains on recent volatility.

Just to be clear, I have been accumulating for past 5+ years with a very substantial position. Moreover, I have a very strong research and active clinical background in hospital medicine. This remains one of my largest positions which I expect to receive my highest return on investment. However, patience will be rewarded - trial results and partnerships take time to materialize. Like others have stated, with experience in small biotech, I anticipate we are likely 3 to 6 months from real significant news that will transform this company. Let's not overly hype this Thursday to be something it's not. Stay the course!!

Quick poll: should I upgrade my July 4th BBQ to steaks and good scotch in anticipation of a 2H 2017 partnership or grab some more relatively cheap shares on Thursday?

Already pretty heavy loaded with my accumulation over past 5+ years.

Naked shorts going to get burned this summer:)

Making CTIX/IPIX strong again!!

Happy July 4th to all.

Yes, correct.

Shares of a small biotech company are surging 75% based on a small 14 patient phase 1b trial for an ovarian cancer trial.

We have multiple trials for multiple indications with multiple different drugs and formulations.

We will have our moment to shine within the next year, patience will be rewarded!!

That is certainly a good reminder in general about the disadvantages of the internet, and in particular, of the past short attacks and fake news that we have experienced over the past 2 years here.

Fortunately, CTIX management has made extraordinary efforts to keep us posted with a steady stream of press releases so we have reliable and accountable information. As in any good business, strategy needs to constantly evolve based on available resources, market timing, and many other known and unknown variables. This comes at a potential risk, because some trials don't meet initial stated goals, however, that doesn't mean management was not honest. We need to remember and appreciate that management is trying to keep us continually updated, and most importantly, our investment objectives are aligned with theirs.

I eagerly look forward to June conference call even to just hear that everything is on track. July conference is a month away where we will likely hear some new and completed data regarding Brilacidin UP trial. More news regarding prurisol trial should follow shortly after in 3rd quarter. We are lucky to have several trials running simultaneously , which should provide nice stream of good news. Patience is a virtue, and likely also will be profitable.

It all depends how much they are willing to pay. Cellceutix may do better selling individual indications separately. This is the benefit of having management interests strongly aligned with us shareholders.